Literature DB >> 18338334

The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.

J M Lucas1, L True, S Hawley, M Matsumura, C Morrissey, R Vessella, P S Nelson.   

Abstract

Transmembrane serine protease 2 (TMPRSS2) is an androgen-regulated member of the type two transmembrane protease (TTSP) family. Two other members of the TTSP family, matriptase and hepsin, are over-expressed in prostate adenocarcinoma and mechanistically influence cancer cell invasion and metastasis. This study was performed to determine TMPRSS2 protein expression in primary and metastatic prostate cancers. We developed a monoclonal antibody capable of the sensitive and specific detection of TMPRSS2 protein. TMPRSS2 regulation by androgen and presence in seminal fluid was measured. TMPRSS2 localization and expression was evaluated in 415 cases of primary prostate cancer and 144 prostate cancer metastases by immunohistochemistry. We determined that TMPRSS2 protein expression is regulated by androgens and that TMPRSS2 is a component of the normal seminal fluid proteome. TMPRSS2 protein is abundantly expressed in the prostate, with low levels in the epithelia of the colon, stomach, epididymis and breast. Pancreatic acini, hepatic bile ducts, testicular Leydig cells and the kidney also express TMPRSS2. In the prostate, TMPRSS2 protein is specifically localized to the secretory epithelium, with enhanced expression in the plasma membrane orientated towards the ductal lumen. TMPRSS2 expression was significantly higher in both neoplastic prostate and in the epithelium of prostatic hyperplasia compared to normal epithelium (p < 0.01). TMPRSS2 expression was further elevated in higher Gleason grade cancers (patterns 4 and 5) compared to pattern 3 (p = 0.04). Furthermore, in most high-grade cancers, TMPRSS2 was mislocalized, being expressed in the cytoplasm as well as in the cell membrane. Prostate cancer metastases also generally expressed high levels of TMPRSS2. In summary, the TMPRSS2 protease is expressed highly in primary and metastatic prostate cancers and is associated with tumour cell differentiation. Based on studies with the related proteins matriptase and hepsin, TMPRSS2 should be investigated for causal roles in prostate carcinogenesis. Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338334     DOI: 10.1002/path.2330

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  56 in total

1.  Insights into the mechanism of organ-specific cancer metastasis.

Authors:  Mark A Rubin
Journal:  Cancer Discov       Date:  2014-11       Impact factor: 39.397

Review 2.  The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.

Authors:  Toni M Antalis; Marguerite S Buzza; Kathryn M Hodge; John D Hooper; Sarah Netzel-Arnett
Journal:  Biochem J       Date:  2010-06-15       Impact factor: 3.857

3.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Authors:  Jared M Lucas; Cynthia Heinlein; Tom Kim; Susana A Hernandez; Muzdah S Malik; Lawrence D True; Colm Morrissey; Eva Corey; Bruce Montgomery; Elahe Mostaghel; Nigel Clegg; Ilsa Coleman; Christopher M Brown; Eric L Schneider; Charles Craik; Julian A Simon; Antonio Bedalov; Peter S Nelson
Journal:  Cancer Discov       Date:  2014-08-13       Impact factor: 39.397

4.  TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells.

Authors:  Ya-Wen Chen; Ming-Shyue Lee; Amanda Lucht; Feng-Pai Chou; Wei Huang; Thomas C Havighurst; KyungMann Kim; Jehng-Kang Wang; Toni M Antalis; Michael D Johnson; Chen-Yong Lin
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

5.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

6.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Authors:  Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

7.  TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice.

Authors:  Carolin Tarnow; Géraldine Engels; Annika Arendt; Folker Schwalm; Hanna Sediri; Annette Preuss; Peter S Nelson; Wolfgang Garten; Hans-Dieter Klenk; Gülsah Gabriel; Eva Böttcher-Friebertshäuser
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2.

Authors:  Yuta Shirogane; Makoto Takeda; Masaharu Iwasaki; Nobuhisa Ishiguro; Hiroki Takeuchi; Yuichiro Nakatsu; Maino Tahara; Hideaki Kikuta; Yusuke Yanagi
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Changes in the distribution of type II transmembrane serine protease, TMPRSS2 and in paracellular permeability in IPEC-J2 cells exposed to oxidative stress.

Authors:  Erzsebet Paszti-Gere; Reka Fanni Barna; Csaba Kovago; Ipoly Szauder; Gabriella Ujhelyi; Csaba Jakab; Nóra Meggyesházi; Andras Szekacs
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

10.  Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.

Authors:  K Mwamukonda; Y Chen; L Ravindranath; B Furusato; Y Hu; J Sterbis; D Osborn; I Rosner; I A Sesterhenn; D G McLeod; S Srivastava; G Petrovics
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-07-14       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.